SUBSCRIBE
SUBSCRIBE

Palleon Pharmaceuticals

NEWS
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Genetown
Palleon Pharma Bursts Onto the Scene With $47.6 Million and a New R&D Approach
October 4, 2017
 · 
2 min read
IN THE PRESS
Drug Development
Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 11, 2022
 · 
2 min read
Business
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
October 5, 2022
 · 
3 min read
Business
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
June 28, 2022
 · 
6 min read
Genetown
Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase
April 8, 2022
 · 
2 min read
Genetown
Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting
March 9, 2022
 · 
2 min read
Drug Development
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
March 8, 2022
 · 
3 min read
FDA
Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology
January 20, 2022
 · 
1 min read
Business
Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors
December 16, 2021
 · 
2 min read
Drug Development
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity
November 9, 2021
 · 
2 min read
Business
Palleon Pharmaceuticals Appoints David Johnson to Its Board of Directors
November 2, 2021
 · 
2 min read
Load More
JOBS